Date:8/31/2009

t of advanced prostate cancer; and SUPPRELIN((R)) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
2. Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
3. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
4. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
5. Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals
6. Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags
7. Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
8. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
9. Cumberland Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009
11. Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.